Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
-
Published:2023-12
Issue:6
Volume:8
Page:102034
-
ISSN:2059-7029
-
Container-title:ESMO Open
-
language:en
-
Short-container-title:ESMO Open
Author:
Tomita Y.ORCID,
Motzer R.J.ORCID,
Choueiri T.K.ORCID,
Rini B.I.ORCID,
Miyake H.ORCID,
Oya M.ORCID,
Albiges L.ORCID,
Aizawa M.,
Umeyama Y.ORCID,
Wang J.,
di Pietro A.,
Schmidinger M.
Funder
Merck
Merck KGaA
Pfizer
Subject
Cancer Research,Oncology